Genetics of Coronary Artery Disease in Type 2 Diabetes

2 型糖尿病冠状动脉疾病的遗传学

基本信息

  • 批准号:
    7895595
  • 负责人:
  • 金额:
    $ 63.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-29 至 2013-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Diabetes mellitus is one of the most potent risk factors for coronary artery disease (CAD). This effect results from an acceleration of atherosclerosis induced by hyperglycemia and other aspects of the diabetic milieu. To decrease the cardiovascular burden of this disease, a better understanding of the mechanisms linking diabetes to atherosclerosis is needed, so that new interventions specifically targeted to diabetic subjects can be developed. Our strategy is to gain this knowledge through genetic studies. Genetic factors have long been recognized as important modulators of cardiovascular risk in both the general and the diabetic populations. Evidence from our group indicates that some of these genes may have a synergistic effect with hyperglycemia, resulting into an especially strong effect in the diabetic population. Using a novel DNA-pooling approach, we have completed the first stage of a 300,000 SNP genome-wide association (GWA) study in a small set of CAD-positive and CAD-negative individuals with type 2 diabetes (T2D) from the Joslin Heart Study (JHS). This study has led to the identification of several SNPs showing large differences in allele frequencies between cases and controls, some of which cluster at loci on chromosomes 2, 5, 6, 9, and 14. The specific aims of the present application are: 1. to complete the GWA study in an expanded set (n=2600) of CAD cases and controls from the JHS. The larger sample size will provide the power to discriminate true associations from false positive results due to multiple testing. 2. To replicate significant findings of association with CAD in T2D in an independent set of cases and controls (n=3200) from the Nurses Health Study and Health Professional Follow-up Study. Replication will enhance the confidence in positive results and will allow more precise estimates of the magnitude of genetic effects. 3. Identify candidate causal variants in the genomic regions showing association with CAD in T2D. Identification of possible functional variants will provide insights on the cellular pathways that modulate the risk of CAD in T2D. Three important features distinguish this study. First, this project has high probability of success, as indicated by our recent identification of a CAD risk allele interacting with hyperglycemia on chromosome 9p21. Second, it concerns a topic that has been so far overlooked by genetic studies. None of the GWA studies that were completed or are in progress are focused on CAD in diabetes, in part because few other investigators have access to large numbers of individuals with CAD and T2D. Third, this research has great significance. Being an unbiased, whole- genome study, it has the potential to identify new molecular pathways linking diabetes to atherogenesis with obvious implications for the development of new drugs specifically targeted to the prevention or treatment of CAD among diabetic patients. PUBLIC HEALTH RELEVANCE: The goal of this project is to identify genes involved in the modulation of coronary artery disease among individuals with type 2 diabetes. This knowledge may point to as yet undiscovered disease mechanisms and suggest novel strategies for developing new pharmacological interventions for preventing or treating this complication of diabetes. Availability of genetic markers of increased susceptibility to CAD would also allow the identification of diabetic individuals at increased risk of cardiovascular disease, so that preventive programs can be specifically targeted at these subjects early in life.
描述(由申请人提供):糖尿病是冠状动脉疾病(CAD)最重要的危险因素之一。这种影响是由高血糖和糖尿病环境的其他方面引起的动脉粥样硬化加速引起的。为了减少这种疾病的心血管负担,需要更好地了解糖尿病与动脉粥样硬化之间的机制,以便开发专门针对糖尿病受试者的新干预措施。我们的策略是通过基因研究来获得这些知识。遗传因素长期以来被认为是普通人群和糖尿病人群心血管风险的重要调节因素。我们小组的证据表明,其中一些基因可能与高血糖有协同作用,在糖尿病人群中产生特别强烈的作用。使用一种新的dna池方法,我们在Joslin心脏研究(JHS)的一小组cad阳性和cad阴性2型糖尿病(T2D)患者中完成了30万个SNP全基因组关联(GWA)研究的第一阶段。这项研究已经鉴定出几个snp,显示病例和对照之间的等位基因频率存在很大差异,其中一些聚集在染色体2、5、6、9和14的位点上。本申请的具体目的是:1。在JHS的CAD病例和对照组的扩展集(n=2600)中完成GWA研究。更大的样本量将提供区分真实关联和由于多次检测而产生的假阳性结果的能力。2. 在一组独立的病例和对照(n=3200)中,从护士健康研究和卫生专业人员随访研究中复制与冠心病相关的重要发现。复制将增强对积极结果的信心,并将允许更精确地估计遗传效应的大小。3. 在T2D中确定与CAD相关的基因组区域的候选因果变异。识别可能的功能变异将提供对调节T2D中CAD风险的细胞途径的见解。本研究有三个重要特征。首先,这个项目有很高的成功概率,正如我们最近在染色体9p21上发现的与高血糖相互作用的CAD风险等位基因所表明的那样。其次,它涉及到一个迄今为止被基因研究所忽视的主题。没有一项已经完成或正在进行的GWA研究关注冠心病在糖尿病中的作用,部分原因是其他研究者很少有机会接触到大量的冠心病和T2D患者。第三,本研究具有重要意义。作为一项无偏倚的全基因组研究,它有可能确定将糖尿病与动脉粥样硬化联系起来的新分子途径,对开发专门针对糖尿病患者预防或治疗冠心病的新药具有明显的意义。公共卫生相关性:该项目的目标是确定参与2型糖尿病患者冠状动脉疾病调节的基因。这些知识可能指向尚未发现的疾病机制,并为开发新的药物干预措施预防或治疗糖尿病并发症提供新的策略。对CAD易感性增加的遗传标记的可用性也将允许识别心血管疾病风险增加的糖尿病个体,因此预防方案可以在生命早期专门针对这些受试者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alessandro Doria其他文献

Alessandro Doria的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alessandro Doria', 18)}}的其他基金

Early myocardial remodeling and progressive kidney function decline in type 1 diabetes
1 型糖尿病的早期心肌重塑和进行性肾功能下降
  • 批准号:
    10544058
  • 财政年份:
    2021
  • 资助金额:
    $ 63.15万
  • 项目类别:
A pilot study of fenofibrate to prevent kidney function loss in type 1 diabetes
非诺贝特预防 1 型糖尿病肾功能丧失的初步研究
  • 批准号:
    10471906
  • 财政年份:
    2021
  • 资助金额:
    $ 63.15万
  • 项目类别:
A pilot study of fenofibrate to prevent kidney function loss in type 1 diabetes
非诺贝特预防 1 型糖尿病肾功能丧失的初步研究
  • 批准号:
    10274529
  • 财政年份:
    2021
  • 资助金额:
    $ 63.15万
  • 项目类别:
A pilot study of fenofibrate to prevent kidney function loss in type 1 diabetes
非诺贝特预防 1 型糖尿病肾功能丧失的初步研究
  • 批准号:
    10675516
  • 财政年份:
    2021
  • 资助金额:
    $ 63.15万
  • 项目类别:
Early myocardial remodeling and progressive kidney function decline in type 1 diabetes
1 型糖尿病的早期心肌重塑和进行性肾功能下降
  • 批准号:
    10371705
  • 财政年份:
    2021
  • 资助金额:
    $ 63.15万
  • 项目类别:
Genotype-dependent cardiovascular and anti-inflammatory effects of fenofibrate
非诺贝特的基因型依赖性心血管和抗炎作用
  • 批准号:
    10223436
  • 财政年份:
    2020
  • 资助金额:
    $ 63.15万
  • 项目类别:
Genotype-dependent cardiovascular and anti-inflammatory effects of fenofibrate
非诺贝特的基因型依赖性心血管和抗炎作用
  • 批准号:
    10043522
  • 财政年份:
    2020
  • 资助金额:
    $ 63.15万
  • 项目类别:
PERL: A multi-center clinical trial of allopurinol to prevent GFR loss in T1D
PERL:别嘌呤醇预防 T1D 患者 GFR 损失的多中心临床试验
  • 批准号:
    9738022
  • 财政年份:
    2013
  • 资助金额:
    $ 63.15万
  • 项目类别:
PERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1D
PERL:别嘌呤醇预防 T1D 患者 GFR 损失的多中心临床试验
  • 批准号:
    8644403
  • 财政年份:
    2013
  • 资助金额:
    $ 63.15万
  • 项目类别:
A multicenter clinical trial of allopurinol to prevent GFR loss in T1D
别嘌呤醇预防 1 型糖尿病 GFR 损失的多中心临床试验
  • 批准号:
    8445008
  • 财政年份:
    2012
  • 资助金额:
    $ 63.15万
  • 项目类别:

相似海外基金

SHINE: Origin and Evolution of Compressible Fluctuations in the Solar Wind and Their Role in Solar Wind Heating and Acceleration
SHINE:太阳风可压缩脉动的起源和演化及其在太阳风加热和加速中的作用
  • 批准号:
    2400967
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328975
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Continuing Grant
EXCESS: The role of excess topography and peak ground acceleration on earthquake-preconditioning of landslides
过量:过量地形和峰值地面加速度对滑坡地震预处理的作用
  • 批准号:
    NE/Y000080/1
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Research Grant
Market Entry Acceleration of the Murb Wind Turbine into Remote Telecoms Power
默布风力涡轮机加速进入远程电信电力市场
  • 批准号:
    10112700
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Collaborative R&D
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328973
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Continuing Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328972
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Continuing Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332916
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Standard Grant
Collaborative Research: A new understanding of droplet breakup: hydrodynamic instability under complex acceleration
合作研究:对液滴破碎的新认识:复杂加速下的流体动力学不稳定性
  • 批准号:
    2332917
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Standard Grant
Collaborative Research: FuSe: R3AP: Retunable, Reconfigurable, Racetrack-Memory Acceleration Platform
合作研究:FuSe:R3AP:可重调、可重新配置、赛道内存加速平台
  • 批准号:
    2328974
  • 财政年份:
    2024
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Continuing Grant
Radiation GRMHD with Non-Thermal Particle Acceleration: Next-Generation Models of Black Hole Accretion Flows and Jets
具有非热粒子加速的辐射 GRMHD:黑洞吸积流和喷流的下一代模型
  • 批准号:
    2307983
  • 财政年份:
    2023
  • 资助金额:
    $ 63.15万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了